NEW YORK (GenomeWeb News) – Becton Dickinson said last night that it has acquired all of the outstanding stock of privately held Cytopeia, which makes advanced flow cytometry cell sorting instruments.
BD did not disclose financial terms of the acquisition but said that is not expected to have a material impact on the firm’s 2008 earnings.
Franklin Lakes, NJ-based BD said that Cytopeia’s Influx cell sorter provides the firm with an open, configurable cell sorting platform that can be fully optimized for application-specific requirements. It said the Influx could be used in cell therapy research, stem cell research, drug discovery and development, and marine biology applications and is complementary to its FACSAria II system.
Seattle-based Cytopeia was the first spin-off from the Institute for Systems Biology.
Cytopeia President and Chief Technology Officer Ger van den Engh will join BD Biosciences as VP of Advanced Cytometry and continue research and technology development activities in Seattle, said BD.